Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors
Clinical manifestations and prognostic factors in patients with gastrointestinal stromal tumors作者机构:DivisionofGastroenterologyDepartmentofInternalMedicineMackayMemorialHospitalTaipeiTaiwanandMackayJuniorCollegeofNursingTaipeiTaiwanChina DivisionofHematology-OncologyDepartmentofInternalMedicineMackayMemorialHospitalTaipeiTaiwanChina DepartmentofPathologyMackayMemorialHospitalTaipeiTaiwanChina DepartmentofSurgeryMackayMemorialHospitalTaipeiTaiwanandMackayJuniorCollegeofNursingTaipeiTaiwanChina
出 版 物:《World Journal of Gastroenterology》 (世界胃肠病学杂志(英文版))
年 卷 期:2003年第9卷第12期
页 面:2809-2812页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:胃肠道基质肿瘤 临床表现 预测因子 早期诊断 免疫组织化学
摘 要:AIM: To investigate the incidence of CD117-positive immunohistochemical staining in previously diagnosed gastrointestinal (GI) tract stromal tumors (GTST) and to analyze the tumors clinical manifestations and prognostic ***: We retrospectively reviewed 91 cases with a previous diagnosis of GI stromal tumor, leiomyoma, or leiomyosarcoma. Tissue samples were assessed with CD117, CD34, SMA and S100 immunohistochemical staining. Clinical and pathological characteristics were analyzed for prognostic ***: CD117 was positive in 81 (89 %) of 91 tissue samples. There were 59 cases (72.8 %) positive for CD34,13 (16 %) positive for SMA, and 12 (14.8 %) positive for S100. There was no gender difference in patients with CD117-positive GIST. Their mean age was 65 years. There were 44 (54 %) tumors located in the stomach and 29 (36 %)in the small intestine. The most frequent presenting symptoms were abdominal pain and GI bleeding. The mean tumor size was 7.5±5.7 cm. There were 35 cases (43.2 %)with tumors 5 cm. The tumor size correlated significantly with tumor mitotic count and resectability. Tumor size, mitotic count, and resectability correlated significantly with tumor recurrence and survival. There was recurrent disease in 39 % of our patients, and their mean survival after recurrence was 16.6 months. Most recurrences were at the primary site or metastatic to the liver. Twenty-six percent of our patients died of their ***: Traditional histologic criteria are not specific enough to diagnose GIST. This diagnosis must be confirmed with CD117 immunohistochemical staining. Prognosis is dependent on tumor size, mitotic count, and resectability.